Newsroom | 170769 results
Sorted by: Latest
-
Atropos Health Expands Oncology Precision Medicine Capabilities with Publication of New AI Algorithms for Rare Disease and Integration of ASCO Guidelines
PALO ALTO, Calif.--(BUSINESS WIRE)--Atropos Health, a pioneer in translating real-world clinical data into personalized real-world evidence (RWE) and insights, today announced the publication of additional AI tools for patient monitoring for existing paroxysmal nocturnal hemoglobinuria (PNH)—a rare, serious blood disorder. The progression monitoring tools are in addition to the previously-published algorithm to improve earlier diagnosis that was announced prior. Atropos Health has developed add...
-
HCA Healthcare Announces $4.8 Million Gift to Help Launch Pepperdine University’s School of Nursing
NASHVILLE, Tenn.--(BUSINESS WIRE)--HCA Healthcare, Inc. (NYSE:HCA), one of the nation’s leading healthcare providers, today announced it will give $4.8 million to Pepperdine University to help launch the School of Nursing within the College of Health Science. This is part of HCA Healthcare’s greater commitment to helping address the national nursing shortage. “We believe that investing in nursing education is vital to the future of healthcare,” said Sammie Mosier, DHA, MA, BSN, NE-BC, senior vi...
-
Amylyx Pharmaceuticals Announces New Safety and Tolerability Cohort 1 Data of AMX0114 in ALS from First-in-Human LUMINA Trial
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals Announces New Safety and Tolerability Cohort 1 Data of AMX0114 in ALS from First-in-Human LUMINA Trial...
-
Actio Biosciences Announces Preclinical Data Highlighting Ability of ABS-1230 to Potently and Selectively Inhibit KCNT1 and Significantly Reduce Seizure Activity
SAN DIEGO--(BUSINESS WIRE)--Actio Biosciences, a clinical-stage biotechnology company advancing the translation of genetic insights into novel precision medicines, today announced preclinical data related to the company’s co-lead candidate ABS-1230, a selective small molecule KCNT1 inhibitor for the treatment of KCNT1-related epilepsy. The data are being presented today, December 5, in a platform presentation by Actio CSO David Breckenridge, Ph.D., from 3:30-5:45 p.m. at the American Epilepsy S...
-
Stoke Therapeutics and Biogen Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting
BEDFORD, Mass. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, and Biogen Inc. (Nasdaq: BIIB) today announced data presentations that further support the potential of zorevunersen, an investigational antisense oligonucleotide, as a disease-modifying medicine for Dravet syndrome. These data were presented at the 2025 American Epilepsy Society (AES)...
-
Owlet Launches TGA-Approved Dream Sock™ in Australia & New Zealand, Expanding International Footprint and Bringing Trusted Pediatric Health Monitoring to More Families Worldwide
SYDNEY--(BUSINESS WIRE)--Owlet, Inc. (“Owlet” or the “Company”) (NYSE: OWLT), the pioneer of smart infant monitoring, today announces that Dream Sock™ is now available for families across Australia and New Zealand. Dream Sock recently received approval from Australia’s Therapeutic Goods Administration (TGA), meeting rigorous medical device standards in the region. With this milestone achieved, families can now purchase Dream Sock through Owlet’s local website and select retail partners. “Bringi...
-
Zoetis Receives Health Canada Approval for Portela™(relfovetmab injection) to Alleviate Pain Associated with Osteoarthritis in Cats
PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. today announced that Health Canada has approved Portela™ (relfovetmab injection) for the alleviation of pain associated with osteoarthritis (OA) in cats. Designed to provide three months of OA pain relief with a single injection, Portela targets anti-nerve growth factor (NGF), which is a key mediator of OA pain and inflammation. In a nine-month field trial in Europe, Portela demonstrated effectiveness in alleviating OA pain and was found to be well...
-
Guardant Health to Present 14 Abstracts Demonstrating the Power of Multiomic Liquid Biopsy Tests in Predicting Outcomes and Tailoring Treatment for Early and Metastatic Breast Cancer at the 2025 San Antonio Breast Cancer Symposium
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, will present a total of 14 abstracts with its research collaborators from multiple studies demonstrating the value of its tissue-free liquid biopsy tests at the 2025 San Antonio Breast Cancer Symposium (SABCS), taking place Dec. 9–12, 2025. Oral presentations will highlight results generated with Guardant Reveal, the company’s tissue-free test for detecting minimal residual disease (MRD...
-
CONMED Corporation Announces Strategic Exit from Gastroenterology Product Lines
LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced its intention to exit its gastroenterology product lines as part of its broader portfolio optimization strategy. This exit allows CONMED to fully align operations and resources within its core markets—minimally invasive, robotic, and laparoscopic surgery, smoke evacuation, and the surgical treatment of orthopedic soft tissue repair. “Today’s announcement reflects a positive step in our strategic portfolio review and o...
-
Asahi Kasei Strengthens Long-Term Profitability by Phasing Out HMD Production as Part of Structural Reform
TOKYO--(BUSINESS WIRE)--Asahi Kasei will discontinue production of hexamethylene diamine (HMD) as part of its ongoing portfolio optimization....
